SCHEMBL2196247

SCHEMBL2196247

CNC(=O)Nc1ccc(S(=O)(=O)Nc2nnc(C)s2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 4/20 0.64
ALDH1A1 P00352 4/20 0.61
LMNA P02545 1/20 0.61
PKM P14618 3/20 0.59
HPGD P15428 1/20 0.59
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
KLKB1 P03952 1/20 0.57
CTSB P07858 1/20 0.57
ELANE P08246 1/20 0.57
CA1 P00915 2/20 0.55
CA2 P00918 2/20 0.55
CA9 Q16790 1/20 0.55
HSD17B10 Q99714 1/20 0.54
P2RY1 P47900 1/20 0.54
POLB P06746 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
BDKRB1 P46663 1/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL286629 0.87 ALDH1A1 (0.71) AKT1ALDH1A1LMNAPKMHPGD
SCHEMBL2178178 0.85 PKM (0.74) AKT1ALDH1A1LMNAPKMHPGD
SCHEMBL2178229 0.84 ALDH1A1 (0.71) AKT1ALDH1A1LMNAPKMHPGD
SCHEMBL11893077 0.84 AKT1 (0.76) AKT1ALDH1A1LMNAPKMHPGD
SCHEMBL5391648 0.81 SMN1; SMN2 (0.64) AKT1ALDH1A1LMNAPKMHPGD
SCHEMBL2176360 0.79 ALDH1A1 (0.73) AKT1ALDH1A1LMNAPKMHPGD
SCHEMBL11893082 0.79 ALDH1A1 (0.77) AKT1ALDH1A1LMNAPKMHPGD
Phthalylsulfamethizole SCHEMBL2734629 0.79 CYP3A4 (0.65) AKT1ALDH1A1LMNAPKMHPGD
SCHEMBL13212282 0.78 SMN1; SMN2 (0.67) AKT1ALDH1A1LMNAPKMHPGD
SCHEMBL282503 0.78 AKT1 (1.00) AKT1ALDH1A1LMNAPKMMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2013-01-24 US disclosed
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2013-01-24 US disclosed
WO-2011082400-A2 MODULATORS OF IMMUNOINHIBITORY RECEPTOR PD-1, AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-07-07 WO disclosed
WO-2011082400-A2 MODULATORS OF IMMUNOINHIBITORY RECEPTOR PD-1, AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof CD274, PDCD1LG2, PDCD1 AKT1 1602/4885ALDH1A1 380/4885LMNA 4797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.